Sintx Technologies, Inc.
Close on Oct 19, 2026
- Market cap
- $8.24M
- P/E (TTM)
- –
- Dividend yield
- –
About Sintx Technologies
Surgical & Medical Instruments & Apparatus, SIC 3841
SINTX Technologies develops, manufactures, and commercializes advanced silicon nitride ceramics, composites, and devices for medical, antipathogenic, and technical applications. The company provides biomedical solutions specializing in silicon nitride for musculoskeletal and antipathogenic uses, including spinal fusion implants and reconstructive foot and ankle osteotomy wedge systems. In addition, it fabricates ceramic components for electrical, aerospace, and industrial sectors, alongside antipathogenic powders intended for incorporation into masks, drapes, filters, sutures, and wound care devices. SINTX serves commercial customers in medical and industrial markets, as well as government agencies.
The company conducts its operations from a 30,764-square-foot corporate facility in Salt Lake City, Utah, which houses a 19,000-square-foot manufacturing space equipped for powder processing, spray drying, pressing, machining, sintering, and testing. Its products are primarily sold in the United States, while spinal implants featuring its silicon nitride technology have also been implanted in Europe, South America, and Asia. SINTX is headquartered in Salt Lake City, Utah.
Summary of the business section of Sintx Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Sintx Technologies, Inc.
- Founded
- 1996
- Headquarters
- Salt Lake City, UT
- Address
- 1885 West 2100 Street 84119
- Phone
- (801) 839-3516
- Website
- sintx.com
- Employees
- 32, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- TANNER LLP, Lehi, Utah
Stock & identifiers
- Ticker
- SINT
- Exchange
- Nasdaq
- Shares outstanding
- 7M, Aug 5, 2026
- Public float
- $7.65M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-200 reverse, Aug 13, 2024; 1-for-200 reverse, May 28, 2024; 1-for-100 reverse, Mar 29, 2023; 1-for-100 reverse, Dec 20, 2022; 1-for-30 reverse, Aug 14, 2019; 1-for-30 reverse, Jul 29, 2019; 1-for-12 reverse, Nov 16, 2017; 1-for-15 reverse, Mar 23, 2016; 1-for-15 reverse, Jan 25, 2016
- SEC CIK
- 1269026
- CUSIP
- 829392703
- ISIN
- US8293927039
- LEI
- 549300DWWSMS2K42ZP12
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eric K. Olson | Chairman, President and CEO, Director | 30,775 |
| Gregg R. Honigblum | Chief Investment Officer, Director | 196,067 |
| Robert Ryan Elmore | President | 4,910 |
| Kevin Trask | Chief Financial Officer | 4,376 |
| Christopher Michael Lyons | Director | 8,292 |
| Jay M. Moyes | Director | 10,250 |
| Mark Lewis Anderson | Director | 18,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 BSonny Bal | $440.65K | $411.27K | $369.82K | $-100 | – |
| FY2024 Eric Olson | $194.59K | $194.59K | $369.82K | $-100 | – |
| FY2024 Non Peo Neo | – | $355.19K | $369.82K | $-100 | – |
| FY2023 BSonny Bal | $537.31K | $461.68K | $453.60K | $-96 | – |
| FY2023 Eric Olson | $537.31K | $461.68K | $453.60K | $-96 | – |
| FY2023 Non Peo Neo | – | $403.13K | $453.60K | $-96 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“of December 31, 2025, we had 32 employees.”
Corporate history
Events identified from SEC filings